Floatz logo

Edicotinib

Relapsed or Refractory Hodgkin Lymphoma

Janssen Research & Development, LLCSmall moleculePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Relapsed or Refractory Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
M-SYMPATHOL
Affimed GmbH
Phase 2CCC
shr2554
Chinese PLA General Hospital
Phase 1/2CCC
Shr-1701
Chinese PLA General Hospital
Phase 1/2CCC
SEVIPROTIMUT-L
Affimed GmbH
Phase 2CC

Same molecule, other indications

Edicotinib is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
adrenal gland hyperfunctionDormant
C
Indicative ·
39 / 100
View asset →
prostate cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →